AAAAAA

   
Results: 1-25 | 26-30
Results: 1-25/30
LACK OF CORRELATION BETWEEN C-ERBB-2 OVEREXPRESSION AND THE EFFECT OFDOSE-INTENSIFICATION OF ADJUVANT CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER PATIENTS
Authors: THOMSSEN C UNTCH M KONECNY G LEBEAU A DETTMAR P SATTLER D KUHN W KAHLERT S HEPP H GRAEFF H JANICKE F
Citation: C. Thomssen et al., LACK OF CORRELATION BETWEEN C-ERBB-2 OVEREXPRESSION AND THE EFFECT OFDOSE-INTENSIFICATION OF ADJUVANT CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER PATIENTS, European journal of cancer, 34, 1998, pp. 132-132
RANDOMIZED ADJUVANT TRIAL COMPARING 2 DOSE INTENSITIES OF EPIRUBICIN AND CYCLOPHOSPHAMIDE (EC) IN HIGH-RISK BREAST-CANCER
Authors: KONECNY G THOMSSEN C UNTCH M KAHLERT S KUHN W SATTLER D PICHE E LEBEAU A DETTMAR P GRAEFF H JANICKE F
Citation: G. Konecny et al., RANDOMIZED ADJUVANT TRIAL COMPARING 2 DOSE INTENSITIES OF EPIRUBICIN AND CYCLOPHOSPHAMIDE (EC) IN HIGH-RISK BREAST-CANCER, European journal of cancer, 34, 1998, pp. 164-164
TUMORBIOLOGICAL FACTORS (UPA, PAI-1) AS SELECTION CRITERIA FOR ADJUVANT CHEMOTHERAPY IN AXILLARY NODE-NEGATIVE BREAST-CANCER PATIENTS
Authors: JANICKE F THOMSSEN C HARBECK N PRECHTL A BERGER U ULM K DETTMAR P PACHE L SCHMITT M GRAEFF H
Citation: F. Janicke et al., TUMORBIOLOGICAL FACTORS (UPA, PAI-1) AS SELECTION CRITERIA FOR ADJUVANT CHEMOTHERAPY IN AXILLARY NODE-NEGATIVE BREAST-CANCER PATIENTS, European journal of cancer, 34, 1998, pp. 45-45
PHASE III-MULTICENTER TRIAL EPIRUBICIN-PACLITAXEL VS. EPIRUBICIN-CYCLOPHOSPHAMIDE AS FIRST-LINE THERAPY OF METASTATIC BREAST-CANCER - AN AGO STUDY PROTOCOL
Authors: SCHROEDER W LUCK HJ THOMSSEN C MOBUS V KUHN W VONMINCKWITZ G UNTCH M JACKISCH C KOHLER G
Citation: W. Schroeder et al., PHASE III-MULTICENTER TRIAL EPIRUBICIN-PACLITAXEL VS. EPIRUBICIN-CYCLOPHOSPHAMIDE AS FIRST-LINE THERAPY OF METASTATIC BREAST-CANCER - AN AGO STUDY PROTOCOL, Annals of oncology, 9, 1998, pp. 560-560
METASTATIC BREAST-CANCER - EXPERIENCE WITH THE COMBINATION PACLITAXELPLUS EPIRUBICIN
Authors: LUCK HJ THOMSSEN C DUBOIS A UNTCH M LISBOA B KOHLER G DIERGARTEN K
Citation: Hj. Luck et al., METASTATIC BREAST-CANCER - EXPERIENCE WITH THE COMBINATION PACLITAXELPLUS EPIRUBICIN, Oncology, 12(1), 1998, pp. 36-39
IDENTIFICATION OF LOW-RISK NODE-NEGATIVE BREAST-CANCER PATIENTS BY TUMOR BIOLOGICAL FACTORS PAI-1 AND CATHEPSIN-L
Authors: THOMSSEN C OPPELT P JANICKE F ULM K HARBECK N HOFLER H KUHN W GRAEFF H SCHMITT M
Citation: C. Thomssen et al., IDENTIFICATION OF LOW-RISK NODE-NEGATIVE BREAST-CANCER PATIENTS BY TUMOR BIOLOGICAL FACTORS PAI-1 AND CATHEPSIN-L, Anticancer research, 18(3C), 1998, pp. 2173-2180
PROGNOSTIC IMPACT OF TUMOR BIOLOGICAL FACTORS ON SURVIVAL IN NODE-NEGATIVE BREAST-CANCER
Authors: HARBECK N DETTMAR P THOMSSEN C HENSELMANN B KUHN W ULM K JANICKE F HOFLER H GRAEFF H SCHMITT M
Citation: N. Harbeck et al., PROGNOSTIC IMPACT OF TUMOR BIOLOGICAL FACTORS ON SURVIVAL IN NODE-NEGATIVE BREAST-CANCER, Anticancer research, 18(3C), 1998, pp. 2187-2197
SECONDARY AMENORRHEA, SUBJECTIVE SIGNS OF PREGNANCY AND ELEVATED SERUM LEVELS OF HCG CAUSED BY A GIANT-CELL BRONCHOGENIC-CARCINOMA
Authors: DOSE J THOMSSEN C HENKE RP HABERMANN CR BRAENDLE W JANICKE F
Citation: J. Dose et al., SECONDARY AMENORRHEA, SUBJECTIVE SIGNS OF PREGNANCY AND ELEVATED SERUM LEVELS OF HCG CAUSED BY A GIANT-CELL BRONCHOGENIC-CARCINOMA, Geburtshilfe und Frauenheilkunde, 58(1), 1998, pp. 54-57
DOSE-INTENSIFIED VERSUS STANDARD CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER PATIENTS - PRELIMINARY DATA OF A RANDOMIZED TRIAL
Authors: THOMSSEN C UNTCH M SCHILL E SATTLER D KONECNY G BAUERNFEIND P JANICKE F GRAEFF H
Citation: C. Thomssen et al., DOSE-INTENSIFIED VERSUS STANDARD CHEMOTHERAPY IN HIGH-RISK BREAST-CANCER PATIENTS - PRELIMINARY DATA OF A RANDOMIZED TRIAL, European journal of cancer, 33, 1997, pp. 662-662
LONG-TERM PROGNOSTIC IMPACT OF PAI-1 IN PRIMARY BREAST-CANCER CONFIRMED BY 6-YEAR MEDIAN FOLLOW-UP
Authors: HARBECK N THOMSSEN C HENSELMANN B DETTMAR P PRECHTL A PACHE L KUHN W HOFLER H JANICKE F SCHMITT M GRAEFF H
Citation: N. Harbeck et al., LONG-TERM PROGNOSTIC IMPACT OF PAI-1 IN PRIMARY BREAST-CANCER CONFIRMED BY 6-YEAR MEDIAN FOLLOW-UP, European journal of cancer, 33, 1997, pp. 877-877
CLINICAL IMPACT OF THE PLASMINOGEN ACTIVATION SYSTEM IN TUMOR INVASION AND METASTASIS - PROGNOSTIC RELEVANCE AND TARGET FOR THERAPY
Authors: SCHMITT M HARBECK N THOMSSEN C WILHELM O MAGDOLEN V REUNING U ULM K HOFLER H JANICKE F GRAEFF H
Citation: M. Schmitt et al., CLINICAL IMPACT OF THE PLASMINOGEN ACTIVATION SYSTEM IN TUMOR INVASION AND METASTASIS - PROGNOSTIC RELEVANCE AND TARGET FOR THERAPY, Thrombosis and haemostasis, 78(1), 1997, pp. 285-296
PHASE-II STUDY OF PACLITAXEL AND EPIRUBICIN AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: LUCK HJ THOMSSEN C DUBOIS A UNTCH M LISBOA B KOHLER G DIERGARTEN K
Citation: Hj. Luck et al., PHASE-II STUDY OF PACLITAXEL AND EPIRUBICIN AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER, Seminars in oncology, 24(5), 1997, pp. 35-39
PRELIMINARY-RESULTS OF A PHASE-II STUDY OF EPIRUBICIN AND PACLITAXEL AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: LUCK HJ THOMSSEN C DUBOIS A LISBOA BW UNTCH M KUHNLE H JANICKE F MEERPOHL HG LINDNER C KCNECNY G HECKER D DIERGARTEN K
Citation: Hj. Luck et al., PRELIMINARY-RESULTS OF A PHASE-II STUDY OF EPIRUBICIN AND PACLITAXEL AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC BREAST-CANCER, Seminars in oncology, 24(1), 1997, pp. 13-16
TIME-VARYING PROGNOSTIC IMPACT OF TUMOR BIOLOGICAL FACTORS UROKINASE (UPA), PAI-1 AND STEROID-HORMONE RECEPTOR STATUS IN PRIMARY BREAST-CANCER
Authors: SCHMITT M THOMSSEN C ULM K SEIDERER A HARBECK N HOFLER H JANICKE F GRAEFF H
Citation: M. Schmitt et al., TIME-VARYING PROGNOSTIC IMPACT OF TUMOR BIOLOGICAL FACTORS UROKINASE (UPA), PAI-1 AND STEROID-HORMONE RECEPTOR STATUS IN PRIMARY BREAST-CANCER, British Journal of Cancer, 76(3), 1997, pp. 306-311
PROGNOSTIC IMPACT OF PROLIFERATION-ASSOCIATED FACTORS MIBI (KI-67) AND S-PHASE IN NODE-NEGATIVE BREAST-CANCER
Authors: DETTMAR P HARBECK N THOMSSEN C PACHE L ZIFFER P FIZI K JANICKE F NATHRATH W SCHMITT M GRAEFF H HOFLER H
Citation: P. Dettmar et al., PROGNOSTIC IMPACT OF PROLIFERATION-ASSOCIATED FACTORS MIBI (KI-67) AND S-PHASE IN NODE-NEGATIVE BREAST-CANCER, British Journal of Cancer, 75(10), 1997, pp. 1525-1533
INCIDENCE OF STREPTOCOCCUS-PNEUMONIAE INFECTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: GUENTHER C HOLLER E MUTH A LEDDEROSE G HAHN J THOMSSEN C EICHHORN P WICK M ROECKEN M PLEWIG G WILMANNS W KOLB HJ
Citation: C. Guenther et al., INCIDENCE OF STREPTOCOCCUS-PNEUMONIAE INFECTION AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Blood, 90(10), 1997, pp. 4405-4405
THE INCIDENCE OF HUMAN PARVOVIRUS B19 INFECTION IN BONE-MARROW TRANSPLANTATION PATIENTS AND ITS IMPACT ON TRANSPLANT-RELATED MORBIDITY AND MORTALITY
Authors: SCHLEUNING M JAGER G HOLLER E HILL W THOMSSEN C DENZLINGER C LORENZ T MUTH A KOLB HJ
Citation: M. Schleuning et al., THE INCIDENCE OF HUMAN PARVOVIRUS B19 INFECTION IN BONE-MARROW TRANSPLANTATION PATIENTS AND ITS IMPACT ON TRANSPLANT-RELATED MORBIDITY AND MORTALITY, Experimental hematology, 24(9), 1996, pp. 651-651
INTERIM ANALYSIS OF A PHASE-II STUDY OF EPIRUBICIN AND PACLITAXEL AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER
Authors: LUCK HJ THOMSSEN C DUBOIS A LISBOA BW UNTCH M KUHNLE H KONECNY G JANICKE F MEERPOHL HG LINDNER C HECKER D DIERGARTEN K
Citation: Hj. Luck et al., INTERIM ANALYSIS OF A PHASE-II STUDY OF EPIRUBICIN AND PACLITAXEL AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER, Seminars in oncology, 23(1), 1996, pp. 33-36
THE IMPORTANCE OF CYTOSTATIC DOSAGES
Authors: THOMSSEN C
Citation: C. Thomssen, THE IMPORTANCE OF CYTOSTATIC DOSAGES, Geburtshilfe und Frauenheilkunde, 56(7), 1996, pp. 102-105
PROGNOSTIC VALUE OF THE CYSTEINE PROTEASES CATHESPINS-B AND CATHEPSIN-L IN HUMAN BREAST-CANCER
Authors: THOMSSEN C SCHMITT M GORETZKI L OPPELT P PACHE L DETTMAR P JANICKE F GRAEFF H
Citation: C. Thomssen et al., PROGNOSTIC VALUE OF THE CYSTEINE PROTEASES CATHESPINS-B AND CATHEPSIN-L IN HUMAN BREAST-CANCER, Clinical cancer research, 1(7), 1995, pp. 741-746
PROGNOSTIC VALUE OF THE CYSTEINE PROTEASES CATHEPSIN-B AND CATHEPSIN-L IN HUMAN BREAST-CANCER (VOL 1, PG 741, 1995)
Authors: THOMSSEN C
Citation: C. Thomssen, PROGNOSTIC VALUE OF THE CYSTEINE PROTEASES CATHEPSIN-B AND CATHEPSIN-L IN HUMAN BREAST-CANCER (VOL 1, PG 741, 1995), Clinical cancer research, 1(10), 1995, pp. 1234-1234
PROGNOSTIC-SIGNIFICANCE OF 2 PROLIFERATIO N-ASSOCIATED FACTORS IN NODE-NEGATIVE BREAST-CANCER - S-PHASE AND MIB1 (KI-67)
Authors: HARBECK N DETTMAR P THOMSSEN C PACHE L ZIFFER P FIZI K JANICKE F NATHRATH W SCHMITT M GRAEFF H
Citation: N. Harbeck et al., PROGNOSTIC-SIGNIFICANCE OF 2 PROLIFERATIO N-ASSOCIATED FACTORS IN NODE-NEGATIVE BREAST-CANCER - S-PHASE AND MIB1 (KI-67), Gynakologisch-geburtshilfliche Rundschau, 35, 1995, pp. 142-147
FLOW CYTOMETRICALLY DETERMINED S-PHASE FRACTION IS A STRONGER PROGNOSTIC FACTOR IN NODE-NEGATIVE BREAST-CANCER THAN IMMUNOHISTOCHEMICALLY DETECTED MIB1 (KI-67)
Authors: HARBECK N DETTMAR P THOMSSEN C PACHE L SCHMITT M JANICKE F GRAEFF H
Citation: N. Harbeck et al., FLOW CYTOMETRICALLY DETERMINED S-PHASE FRACTION IS A STRONGER PROGNOSTIC FACTOR IN NODE-NEGATIVE BREAST-CANCER THAN IMMUNOHISTOCHEMICALLY DETECTED MIB1 (KI-67), European journal of cancer, 31A, 1995, pp. 664-664
PATTERN OF CARBOPLATIN-INDUCED EMESIS
Authors: DUBOIS A VACH W CRAMERGIRAUD U THOMSSEN C GLAUBITZ M FIOLA M AUGENER W BARTSCH W BERGMANN F BIERBAUM W KRAPP J BONING L BONGARTZ U BRUNTSCH U VONBULTZINGSLOWEN F DIETL J FUGER T FULLE HH GATZEMEIER U GROPP C HARTLAPP H HERSCHLEIN HJ HOLTKAMP W HURST U JANICKE F KAUKEL E KLEEBERG U ENGEL E KRAFFT W KUHNLE H LINDEMANN H MARSCHNER N MEERPOHL HG NIEDERLE N OSIEKA R PLANKER M RIESS H SCHMIDT M SCHMOLL HJ SCHUNEMANN H WEINGARTJESSE B WEITZEL H WESTERHAUSEN M WINKELMANN M
Citation: A. Dubois et al., PATTERN OF CARBOPLATIN-INDUCED EMESIS, Anti-cancer drugs, 6(5), 1995, pp. 645-651
TREATMENT OF REFRACTORY SEVERE APLASTIC-ANEMIA WITH GRANULOCYTE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-3
Authors: SCHLEUNING M THOMSSEN C KOLB HJ SAUER HJ WILMANNS W
Citation: M. Schleuning et al., TREATMENT OF REFRACTORY SEVERE APLASTIC-ANEMIA WITH GRANULOCYTE-COLONY-STIMULATING FACTOR AND INTERLEUKIN-3, American journal of hematology, 46(3), 1994, pp. 250-251
Risultati: 1-25 | 26-30